Latest News and Press Releases
Want to stay updated on the latest news?
-
Patent Covers Multiple Component Vaccine for Both Prevention and Treatment ATLANTA, GA, Aug. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a...
-
ATLANTA, GA, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Seeking Improved Immune Response vs mRNA Vaccine Full Patient Enrollment Expected Within Six Months via NewMediaWire — GeoVax Labs, Inc....
-
Progress and Promising Outlook for Gedeptin® and GEO-CM04S1; Phase 2 GEO-CM04S1; Clinical Trial Initiated for Patients with Chronic Lymphocytic Leukemia Company to Host Conference Call and Webcast...
-
GeoVax to Host Second Quarter 2023 Conference Call at 4:30 PM ET ATLANTA, GA, July 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a...
-
Addressing Multiple Strains of Ebolavirus ATLANTA, GA, July 24, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing...
-
Seeking Improved Immune Response vs mRNA Vaccine ATLANTA, GA, July 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing...
-
ATLANTA, GA, July 10, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...
-
ATLANTA, GA, June 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...
-
Spotlight Content on Pandemic Preparedness: Getting Ready for the Next “Disease X” ATLANTA, GA, June 27, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - GeoVax Labs, Inc. (Nasdaq: GOVX), a...
-
ATLANTA, GA, May 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...